



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE,
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA

TEL: 0260-2430027 / 2400639, E-mail: hrm@gtbl.in.net

1 September 2026

To

Listing Department

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block-G

Bandra Kurla Complex

Bandra East, Mumbai 400051

Symbol: GUJTHEM

Department of Corporate Services

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street

Mumbai 400001

Scrip Code: 506879

Sub.: Outcome of the Board meeting held on September 1, 2026.

Dear Sir/Madam

With reference to the captioned subject and as per the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (the SEBI Listing Regulations), this is to inform you that the Board of Directors of Gujarat Themis Biosyn Limited (the Company) at their meeting held today ie on September 1, 2026, has, *inter-alia*, approved the following.

The issuance of up to 82,10,786 fully paid-up equity shares of the Company of face value of Rs. 1 each at an issue price of Rs. 408/- per equity share (including a securities premium of Rs. 407), aggregating up to Rs. 335,00,00,688/-, to the proposed allottees, as detailed in Annexure A, by way of a preferential issue on a private placement basis (the Preferential Issue), in accordance with the provisions of Section 42, 62 and applicable provisions of the Companies Act 2013, SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, SEBI Listing Regulations and applicable laws, and subject to necessary approvals including approval of the shareholders and Stock Exchanges.

The disclosures as required under Regulation 30 of SEBI Listing Regulations are given in Annexures attached herewith.

The meeting of the Board of Directors commenced at 2:30 p.m. and concluded at 3:35 p.m.

This is for your information and records.

Yours faithfully

For Gujarat Themis Biosyn Limited

Vineet Gawankar

Company Secretary & Compliance Officer

Encl.: As above

Annexure A

Sr.	Particulars	Details
1	Type of securities proposed to be issued (viz. equity shares, convertibles, etc.)	Fully paid-up equity Shares of the Company having face value of Rs. 1 each at an issue price of Rs. 408/- each.
2	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Preferential allotment
3	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	The issue of up to 82,10,786 Equity Shares of the Company of face value of Rs. 1 each, as detailed in Annexure A (Investors) by way of a preferential issue on a private placement basis at the issue price of Rs. 408/- per equity share including a Securities Premium of Rs. 407, aggregating Rs. 335,00,00,688/- in accordance with Chapter V of the SEBI ICDR Regulations, and subject to necessary approvals.
4	In case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s):	
a)	Name of the investors	The list of Proposed Allottees is given as Annexure A.
b)	Post allotment of securities - outcome of the subscription	Not Applicable – To be done post allotment
c)	Issue price	Equity Share of face value of Rs. 1 each at Issue Price of Rs. 408 per Equity Share.
d)	Number of investors	Up to 5.
e)	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument	Not Applicable

Annexure A (List of proposed allottees)

No.	Name of Investors / propose allottees	No. of equity shares proposed to be allotted	Amount to be paid, in Rs.
1	Pharmaceutical Business Group (India) Limited (Promoter group)	61,27,453	250,00,00,824
2	Yusuf Khwaja Hamied	2,45,100	10,00,00,800
3	Special Situation India Fund	4,59,558	18,74,99,664
4	India Special Assets Fund III	6,83,823	27,89,99,784
5	ISAF III Onshore Fund	6,94,852	28,34,99,616

Investors mentioned at Sr. 2, 3, 4 and 5 are belong to non-promoter / non-promoter group.